TickerTalks
Browse all tickers →
TickerTalks›$VRTX
VRVRTX

Vertex Pharmaceuticals Incorporated

$VRTX·$121B·Biotechnology·Healthcare
$541.69-1.1%YTD+5.4%1Y+38.2%
Mentions · last 7 days
2026-08-21: 18 posts2026-08-22: 4 posts84+5%
Price updated 2d ago·X counts updated 8d ago
VRVRTX
$VRTXVertex Pharmaceuticals Incorporated
$541.69-1.07%84 posts+5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $VRTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-29

The move is getting stronger, with heavier trading behind it.

Vertex at 92% of range with the Crinetics acquisition closing and healthcare rotation — quality biotech compounder finally re-rating.

Vertex Pharmaceuticals is a leading biotech — the dominant CF (cystic fibrosis) franchise, plus a growing non-opioid pain (VX-548/Journavx) and Type 1 diabetes cell-therapy pipeline, and now Crinetics-added rare-endocrine assets. The setup is a real-business quality compounder accelerating on healthcare-rotation and a specific M&A catalyst.

  • The Q2 print was clean: EPS came in at $4.73 vs a $4.74 consensus (essentially in line), Q1 EPS at $4.47 vs $4.24 beat, and the sell side models FY26 EPS at ~$19.23 rising to ~$25.39 in 2028 — a real EPS compounding curve with 39% operating margin and 86% gross margin, at only 31x trailing earnings.
  • The Crinetics acquisition is the M&A signal: Vertex signed an all-cash $85/share agreement to acquire Crinetics Pharmaceuticals on July 7 — a real, dollar-attached bolt-on that expands the rare-endocrine footprint (paltusotine for acromegaly, other GPCR-targeting programs) and materially extends the pipeline.
  • The strategic tape is landing: healthcare-sector rotation is favoring VRTX alongside MRK, and Jim Lebenthal buying VRTX on Fast Money plus BBIO framed as the "next VRTX" reinforce the constructive frame — RBC's suggestion that VRTX might need to rely on Nav1.7 vs SGMO (with LLY reportedly bidding on SGMO Nav1.7) is a real strategic dynamic to price.

The setup is a real-business quality biotech accelerating with the Crinetics catalyst and healthcare rotation — the November 2 Q3 print is the referee, and the market needs continued CF-franchise growth plus Journavx uptake color. A clean beat plus updated Crinetics integration and Journavx launch metrics extends the accelerating trajectory toward $600; a soft Q3 CF-franchise print or a Journavx uptake disappointment cools the tape from the 92% 52-week range position.

Agrees with X sentimentThe bullish X read on VRTX strengthening in a healthcare rotation (with MRK/NEM/COP), Jim Lebenthal buying VRTX on Fast Money, BBIO framed as the 'next VRTX', RBC's Nav1.7 vs SGMO dynamic (with LLY reportedly bidding on SGMO Nav1.7), and the VRTX 1999 dot-com run cited as inspirational anchor is factually consistent with the announcements and analyst commentary.

What to watch: The November 2 Q3 earnings — need continued CF-franchise growth, Journavx uptake color, Crinetics integration commentary, and reiterated FY26 EPS guide toward the $19.23 consensus. A soft Q3 CF-franchise print or a Journavx uptake disappointment cools the tape from the 92% 52-week range position; a clean beat plus updated Crinetics integration and Journavx launch metrics extends the accelerating trajectory toward $600.

On the calendar: 2026-11-02 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-08-27

Vertex Pharmaceuticals sentiment is confidently bullish. Users highlight VRTX strengthening in a healthcare rotation (with MRK/NEM/COP), Jim Lebenthal buying VRTX on Fast Money, and BBIO framed as the 'next VRTX'. RBC suggests VRTX might need to rely on Nav1.7 vs SGMO (interesting dynamic with LLY reportedly bidding on SGMO Nav1.7). Historical VRTX 1999 dot-com run cited as inspirational anchor. Skepticism is essentially absent; the modal stance is 'buy VRTX — rotation into pharma leaders'.

Read the AI verdict + X sentiment for $VRTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Dominates cystic fibrosis treatment with TRIKAFTA; expanding pipeline covers pain (non-opioid VX-548), APOL1 kidney disease, and type 1 diabetes.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $VRTX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $VRTX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
31.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
17.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
39.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
10.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
23.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
86.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 3, 2026$4.73$4.74-0.2%
Q1 2026May 4, 2026$4.47$4.24+5.4%
Q4 2025Feb 12, 2026$5.03$5.11-1.6%
Q3 2025Nov 3, 2025$4.80$4.57+5.0%
Next earningsMon, Nov 2·consensus EPS $4.80

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.0B+7.8%86.8%38.1%$4.06$1.3B
Q4 FY25$3.2B+10.8%85.6%40.3%$4.69$348.6M
Q3 FY25$3.1B+11.0%86.5%38.6%$4.24$1.1B
Q2 FY25$3.0B+12.1%86.3%38.8%$4.02$927.4M

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$13.1B$13.0B – $13.2B$19.23$18.87 – $19.7117
FY27$14.3B$13.5B – $16.1B$21.40$18.40 – $22.4816
FY28$16.0B$14.1B – $17.9B$25.39$20.50 – $34.0017
FY29$17.8B$17.0B – $19.2B$29.08$27.28 – $32.0114
FY30$19.6B$18.7B – $21.2B$33.22$31.17 – $36.588

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.92%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 253.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Ourania TatsisEVP, Chief Reg. & Quality Off.1.5K sh$787KSellJul 2Duncan MckechnieEVP, Chief Commercial Officer1.5K sh$800KSellJul 1Joy LiuEVP and Chief Legal Officer828 sh$416KSellJun 26Carmen BozicEVP and CMO596 sh$288KSellJun 18Carmen BozicEVP and CMO1.0K sh$471KSellJun 15Carmen BozicEVP and CMO4.1K sh$1.8MSellJun 5Carmen BozicEVP and CMO1.7K sh$785KSellMay 29Carmen BozicEVP and CMO2.0K sh$888KSellMay 15Mark E. BunnageEVP, Chief Scientific Officer33 sh$15KSellMay 15Carmen BozicEVP and CMO1.4K sh$614K
1–10 of 18
+ 20 other (16 awards · 4 returns) in window

See when $VRTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 78-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Vertex Pharmaceuticals Incorporated signed an Agreement and Plan of Merger on July 6, 2026 to acquire Crinetics Pharmaceuticals, Inc. in an all-cash deal at $85.00 per share, with Crinetics surviving as a wholly owned Vertex subsidiary. All outstanding unvested equity (options and RSUs) will accelerate and convert to the right to receive $85.00 (less any exercise price for options). Closing is subject to customary conditions. Transformative acquisition for Vertex, adding Crinetics' endocrine/rare disease pipeline to Vertex's portfolio at a significant cash premium — signals Vertex's intent to diversify beyond its core CF franchise.

8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Vertex Pharmaceuticals held its 2026 Annual Meeting on May 13, 2026. Shareholders elected all 10 director nominees (including CEO Reshma Kewalramani, Jeffrey Leiden, Sangeeta Bhatia, and others) and approved the 2026 Stock and Option Plan, which replaces the 2013 plan. The new plan was approved by the Board on March 27, 2026. Vertex's strong governance and shareholder base typically result in routine approval of management proposals; the new equity plan provides incentive compensation capacity under an updated structure.

8-KOfficer or director changeApr 298-K — Item 5.02: Officer or director change
+ 24 other (7 S-8 POSs · 4 13Gs · 3 proxys · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Ancora Advisors LLC Acquires Shares of 1,127 Vertex Pharmaceuticals Incorporated $VRTXdefenseworld.net·2d ago17,047 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Beacon Pointe Advisors LLCdefenseworld.net·2d agoBreakfast News: Nvidia Crushed It. Who Cares?fool.com·4d agoVertex to Participate in Upcoming September Investor Conferencesbusinesswire.com·5d agoEP Wealth Advisors LLC Acquires New Position in Vertex Pharmaceuticals Incorporated $VRTXdefenseworld.net·8d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $VRTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport